
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
“It didn't happen overnight. The way we built the program was an iterative process,” says Shubham Gupta, MD.
In this video, Shubham Gupta, MD, summarizes elements of the interactive learning course “Building a Gender Affirmation Program: The What, Why, and How?” which was presented at the North Central Section of the American Urological Association Annual Meeting in Chicago, Illinois. Gupta is director of the Surgical Gender Affirmation Program, Urology Institute, University Hospitals, division chief of Reconstructive Urology at UH Cleveland Medical Center, and associate professor at Case Western Reserve University School of Medicine.